10-Q: ASHS Q2 2025: Net Loss Amid Revenue Shifts

American Shared Hospital Services reports a net loss in Q2 2025, driven by decreased leasing revenue and increased operating costs, despite growth in direct patient services.

Summary

• Net loss attributable to American Shared Hospital Services was $(280,000) for the three months ended June 30, 2025, compared to net income of $3,602,000 for the same period in the prior year.
• Net loss attributable to American Shared Hospital Services was $(905,000) for the six months ended June 30, 2025, compared to net income of $3,721,000 for the same period in the prior year.
• Total revenues increased to $7,071,000 for the three months ended June 30, 2025, from $7,056,000 in the prior year, and to $13,183,000 for the six months ended June 30, 2025, from $12,272,000 in the prior year.
• Leasing segment revenue decreased by $328,000 to $3,571,000 for the three months ended June 30, 2025, and by $1,590,000 to $6,562,000 for the six months ended June 30, 2025, primarily due to lower Gamma Knife and PBRT volumes and contract expirations.
• Direct patient services revenue increased by $343,000 to $3,500,000 for the three months ended June 30, 2025, and by $2,501,000 to $6,621,000 for the six months ended June 30, 2025, driven by the RI Acquisition and the Puebla facility.
• Operating loss widened to $(544,000) for the three months ended June 30, 2025, from $(1,000) in the prior year, and to $(1,843,000) for the six months ended June 30, 2025, from $(86,000) in the prior year.
• Working capital decreased by $12,280,000 to $3,573,000 at June 30, 2025, from $15,853,000 at December 31, 2024.
• Cash, cash equivalents, and restricted cash increased by $56,000 to $11,331,000 at June 30, 2025, from $11,275,000 at December 31, 2024.
• Total long-term debt was $19,094,000 as of June 30, 2025.
• Commitments for purchasing and installing three Leksell Gamma Knife Esprit Systems and two Linear Accelerator systems totaled $8,385,000 as of June 30, 2025.
• Total service commitments for Gamma Knife, LINAC, and PBRT equipment were $11,928,000 as of June 30, 2025.

Sentiment

Score: 3

Explanation: The company reported a net loss and significant declines in its core leasing segment, alongside a substantial decrease in working capital and a disclosed material weakness in internal controls. While direct patient services revenue grew due to acquisitions, the overall financial performance for the period is concerning, indicating operational challenges and increased debt burden, despite some positive future outlooks and remediation efforts.

Positives

• Total revenues increased for both the three and six-month periods ended June 30, 2025, demonstrating overall top-line growth.
• Direct patient services revenue significantly increased by $343,000 (Q2) and $2,501,000 (H1) due to the successful integration of the RI Companies acquisition and the operationalization of the Puebla facility.
• The Puebla radiation therapy facility began treating patients in July 2024, contributing to the direct patient services segment's growth.
• The Peru facility signed a new social security contract in May 2025, which is expected to bring additional patient volumes going forward.
• Selling and administrative expenses decreased by $150,000 (Q2) and $221,000 (H1), reflecting cost management efforts.
• Regained compliance with the maximum funded debt to EBITDA ratio covenant on July 1, 2025, after being non-compliant at June 30, 2025.
• Cash and cash equivalents increased slightly by $56,000 during the first six months of 2025.

Negatives

• Reported a net loss attributable to American Shared Hospital Services of $(280,000) for Q2 2025 and $(905,000) for H1 2025, a significant decline from net income in the prior year periods.
• Leasing segment revenue decreased by $328,000 (Q2) and $1,590,000 (H1) due to lower Gamma Knife and PBRT volumes and the expiration of three customer contracts.
• Gamma Knife procedures decreased by 22.4% (76 procedures) for Q2 2025 and 23.0% (141 procedures) for H1 2025.
• PBRT fractions decreased by 9.9% (122 fractions) for Q2 2025 and 22.6% (567 fractions) for H1 2025.
• Total costs of revenue increased significantly by $853,000 (Q2) and $2,950,000 (H1), outpacing revenue growth.
• Operating loss widened considerably to $(544,000) for Q2 2025 and $(1,843,000) for H1 2025.
• Working capital decreased substantially by $12,280,000 from December 31, 2024, indicating a tightening liquidity position.
• Was not in compliance with the maximum funded debt to EBITDA ratio covenant as of June 30, 2025, although compliance was regained on July 1, 2025.
• Reduced the estimate of salvage value for all remaining domestic Gamma Knife units to $0, resulting in a decrease in net income of approximately $10,000 for Q2 2025 and $93,000 for H1 2025.
• Interest and other income, net, decreased by $14,000 (Q2) and $56,000 (H1) due to lower average cash balances.

Risks

• The level of debt could impact financial flexibility and ability to operate the business.
• The market for capital-intensive services is limited, potentially restricting growth opportunities.
• Lowered federal reimbursement rates could negatively impact revenue from services.
• U.S. health care reform legislation may introduce changes that adversely affect operations.
• Competition and alternatives to services could reduce market share and profitability.
• Technological advances and the risk of equipment obsolescence require continuous investment and adaptation.
• Significant investment in the proton beam radiation therapy business carries inherent risks related to its success and market adoption.
• Restrictions in debt agreements may limit operational flexibility.
• Ability to repay indebtedness is crucial, and failure could lead to severe financial consequences.
• Successfully integrating the RI Companies with existing business operations poses integration challenges.
• Breaches in security of information technology could lead to data loss, operational disruption, and reputational damage.
• The small and illiquid market for stock may affect shareholder value and ability to raise capital through equity.
• There is no assurance that financing will be available for current or future projects on acceptable terms.
• International operations in Peru and Ecuador are susceptible to local legislation changes or social and economic factors.
• A material weakness in internal controls over financial reporting exists due to an insufficient number of personnel and resources with experience to create a proper control environment.

Future Outlook

The company expects its Newco Guadalajara facility to begin treating patients in the fourth quarter of 2025. Remaining Esprit upgrades and one LINAC installation are also scheduled for the fourth quarter of 2025 or later at existing customer sites. The company intends to finance substantially all of these commitments and is actively engaged with financing resources. The Peru social security contract, executed in May 2025, is expected to bring additional patient volumes. The company is evaluating the impact of the recently signed One Big Beautiful Bill Act (OBBBA) tax legislation and will reflect any required adjustments in the third quarter ended September 30, 2025. The company expects to manage its billing cycle internally around the fourth quarter of 2025 and will continue to assess the need for additional finance and accounting resources as the business grows.

Management Comments

• The financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.
• The decrease in PBRT volumes for the three and six-month periods ended June 30, 2025, was due to what are believed to be normal, cyclical fluctuations.
• Cash flow from cash on hand and operations is believed to be sufficient to cover service commitments.
• While financing has been secured for past projects and is anticipated for future projects from existing or other lending sources, there can be no assurance that financing will continue to be available on acceptable terms.
• The primary element of the remediation plan for internal controls can only be accomplished over time, and no assurance can be offered that these initiatives will ultimately have the intended effects.

Industry Context

American Shared Hospital Services operates in the specialized medical equipment and healthcare services industry, focusing on advanced radiation therapy for cancer treatment, including Gamma Knife, Proton Beam Radiation Therapy (PBRT), and Linear Accelerator (LINAC) systems. The company's strategy involves both equipment leasing to hospitals and direct patient services through its own facilities, expanding internationally into Peru, Ecuador, and Mexico. The industry is influenced by factors such as federal reimbursement rates (e.g., CMS rates for Medicare Gamma Knife and PBRT treatments), technological advancements, and the capital-intensive nature of the equipment. The company's recent acquisitions, like the RI Companies, reflect a trend towards vertical integration and direct patient care to diversify revenue streams, while also facing challenges related to managing debt, integrating new operations, and navigating local legislative and socio-economic factors in international markets.

Management Changes

Corporate Governance

Related Party Transactions

• Equipment purchases and de-install costs from Elekta: $1,862,000 for the three months ended June 30, 2025, and $3,169,000 for the six months ended June 30, 2025.
• Costs incurred to maintain equipment from Elekta: $200,000 for the three months ended June 30, 2025, and $451,000 for the six months ended June 30, 2025.
• Commitments to purchase and install three Esprit units, two LINACs, and service related equipment from Elekta: $13,387,000 as of June 30, 2025.
• Related party liabilities (accounts payable, asset retirement obligation, and other accrued liabilities): $1,848,000 as of June 30, 2025.

Stakeholder Impact

• Shareholders experienced a net loss and diluted loss per share for the period, indicating reduced profitability.
• Customers benefit from new and upgraded equipment (Esprit, LINAC) and expanded direct patient services facilities (RI Companies, Puebla). However, some customer contracts expired, leading to reduced Gamma Knife availability in certain areas.
• Creditors faced temporary non-compliance with a debt covenant, increasing risk, but compliance was regained. Increased borrowings indicate reliance on debt financing.
• Employees may see increased opportunities due to staffing increases in sales, finance, and customer retention, and plans to hire experienced staff for internal billing.
• Suppliers, particularly Elekta, remain significant partners for equipment purchases and maintenance.

Next Steps

• Install remaining Esprit upgrades and one LINAC system at existing customer sites around Q4 2025 or later.
• Newco Guadalajara facility expected to begin treating patients in Q4 2025.
• Manage billing cycle for Rhode Island facilities internally around Q4 2025.
• Evaluate the impact of the One Big Beautiful Bill Act (OBBBA) tax legislation and reflect adjustments in Q3 2025.
• Continue to assess the need for additional resources, especially in finance and accounting areas.

Key Dates

Recommendation

While the company reported a net loss and faced challenges in its leasing segment with declining volumes and contract expirations, the growth in direct patient services revenue from recent acquisitions (RI Companies, Puebla) shows a strategic shift and potential for future growth. The company has also addressed a debt covenant non-compliance issue and is actively working to remediate internal control weaknesses. Given the mixed performance, ongoing strategic investments, and efforts to improve operations, a 'hold' recommendation is appropriate for investors to observe the effectiveness of these initiatives and the performance of the newer direct patient services segment before making further investment decisions.

Keywords

Radiosurgery, Radiation Therapy, Gamma Knife, Proton Beam Therapy, PBRT, Medical Equipment Leasing, Healthcare Services, SEC Filing, 10-Q, ASHS, Oncology, Cancer Treatment, Medical Devices